MSFP
AUPH icon

Mark Sheptoff Financial Planning’s Aurinia Pharmaceuticals AUPH Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.79K Hold
400
– – ﹤0.01% 415
2026
Q1 		$6.42K Hold
400
– – ﹤0.01% 404
2025
Q4 		$6.38K Buy
+400
New +$5.67K ﹤0.01% 396

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mark Sheptoff Financial Planning's AUPH Position: Q2 2026 in Review

Mark Sheptoff Financial Planning held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 400 shares worth $6.79K. The position accounts for ﹤0.01% of the portfolio, ranked #415.

Mark Sheptoff Financial Planning first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Mark Sheptoff Financial Planning held 400 shares of Aurinia Pharmaceuticals worth $6.79K as of Q2 2026.
  • Mark Sheptoff Financial Planning left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Mark Sheptoff Financial Planning's portfolio in Q2 2026, its #415 holding.
  • Mark Sheptoff Financial Planning first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2026, filed 13 Aug 2026.